Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694758 | 0.82 | ROCK2 (0.44) | ROCK2SLC6A4KCNH2SLC6A2ALDH1A1 | |
| SCHEMBL28216838 | 0.81 | ROCK2 (0.39) | ROCK2 | |
| SCHEMBL16640270 | 0.80 | ROCK2 (0.36) | ROCK2 | |
| SCHEMBL2848628 | 0.77 | ROCK2 (0.38) | ROCK2 | |
| SCHEMBL8000143 | 0.76 | ROCK2 (0.35) | ROCK2MEN1KMT2AMAPTSLC6A4 | |
| SCHEMBL1315359 | 0.75 | ROCK2 (0.35) | ROCK2MEN1KMT2AMAPTKDM4E | |
| SCHEMBL4000419 | 0.75 | ROCK2 (0.43) | ROCK2SLC6A4SLC6A2ALDH1A1 | |
| SCHEMBL16449936 | 0.74 | SLC6A4 (0.32) | MEN1KMT2ASLC6A4KDM4EALDH1A1 | |
| SCHEMBL19178217 | 0.74 | SLC6A4 (0.32) | MEN1KMT2ASLC6A4KDM4EALDH1A1 | |
| SCHEMBL20712553 | 0.74 | SLC6A4 (0.32) | MEN1KMT2ASLC6A4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834529-B2 | Synthesis of benzothiazepines | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GlaxSmithKline Intellectual Propety (No.2) Limited (GB) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210717-A1 | SYNTHESIS OF BENZOTHIAZEPINES | GABBR1, GABRE, GABBR2 | ROCK2 3592/4885MEN1 2027/4885KMT2A 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.